Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.88M Buy
13,480
+9,762
+263% +$3.34M 1.49% 6
2026
Q1
$1.31M Sell
3,718
-680
-15% -$242K 0.63% 74
2025
Q4
$1.44M Sell
4,398
-1,332
-23% -$423K 0.53% 54
2025
Q3
$1.62M Buy
5,730
+1,267
+28% +$367K 0.59% 40
2025
Q2
$1.25M Buy
+4,463
New +$1.26M 0.47% 132
2025
Q1
Sell
-13,095
Closed -$3.41M 58
2024
Q4
$3.41M Buy
+13,095
New +$3.89M 2.11% 27

Other funds holding AMGN

Stance Capital's AMGN Position: Q2 2026 in Review

Stance Capital increased its Amgen (AMGN) stake by 263% in Q2 2026, buying an estimated $3.34M and bringing the position to 13,480 shares worth $4.88M. The position accounts for 1.49% of the portfolio, ranked #6.

Stance Capital first reported a position in AMGN in Q4 2024 and has held it in 6 quarters since. 3,151 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Stance Capital held 13,480 shares of Amgen worth $4.88M as of Q2 2026.
  • Stance Capital bought 9,762 Amgen shares in Q2 2026, an estimated $3.34M.
  • Amgen made up 1.49% of Stance Capital's portfolio in Q2 2026, its #6 holding.
  • Stance Capital first reported a position in Amgen in Q4 2024 and has held it in 6 quarters since.
  • 3,151 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Stance Capital's 13F filing for Q2 2026, filed 14 Aug 2026.